MF-094, a potent and selective USP30 inhibitor (IC50=0.12 μM), accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome.
MF-094 restores viability and migration of AGE-treated HSF2 cells. MF-094 treatment decreases protein levels of NLRP3 and its downstream target caspase-1 p20.[2]
MF-094 treatment facilitates wound healing in diabetic rats.[2]
[1] Kluge AF, et al. Bioorg Med Chem Lett. 2018 Aug 15;28(15):2655-2659. [2] Li X, et al. Exp Cell Res. 2022 Jan 15;410(2):112967.
















